Diagnosis and management of basal cell carcinoma

研究成果: Article

2 引用 (Scopus)

抄録

Basal cell carcinomas (BCCs) are common skin cancers that tend to appear on sun-exposed skin. Pathobiologically, activation of the Hedgehog signaling pathway characterizes the majority of cases. In general, BCCs are slow-growing and rarely metastasize. Nevertheless, they are locally invasive and can be destructive. While typical cases are diagnosed based on clinical findings, the clinicopathological manifestations are varied. Consequently, skin biopsy is essential to confirm the diagnosis and evaluate the risk of recurrence. In the treatment of primary lesions, the initial goal is to complete tumor removal, whether by conventional surgical excision, Mohs micrographic surgery, cryosurgery, electrodesiccation and curettage, topical application of imiquimod or fluorouracil, photodynamic therapy, or radiation therapy. Of these treatments, surgical excision and Mohs surgery are the most commonly used because of their association with a low recurrence rate and the ability to confirm residual tumor pathologically. However, other treatment options may be preferred according to patient condition, tumor location, and risk of recurrence. In the treatment of metastatic or locally advanced lesions, smoothened inhibitors, which inhibit Hedgehog signaling pathway activation, were recently approved and impressive tumor shrinkage effects have been described. Although the exact prognosis of metastatic BCC has not been analyzed, it is probably poor due to the rarity of such condition. However, emerging molecular targeting agents hold therapeutic promise.

元の言語English
記事番号13
ジャーナルCurrent Treatment Options in Oncology
20
発行部数2
DOI
出版物ステータスPublished - 2019 1 1

Fingerprint

Basal Cell Carcinoma
Mohs Surgery
Recurrence
imiquimod
Therapeutics
Neoplasms
Skin
Cryosurgery
Curettage
Photochemotherapy
Residual Neoplasm
Skin Neoplasms
Solar System
Fluorouracil
Radiotherapy
Biopsy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

これを引用

Diagnosis and management of basal cell carcinoma. / Tanese, Keiji.

:: Current Treatment Options in Oncology, 巻 20, 番号 2, 13, 01.01.2019.

研究成果: Article

@article{b75c7da4da7047829af3f87dd8ff861c,
title = "Diagnosis and management of basal cell carcinoma",
abstract = "Basal cell carcinomas (BCCs) are common skin cancers that tend to appear on sun-exposed skin. Pathobiologically, activation of the Hedgehog signaling pathway characterizes the majority of cases. In general, BCCs are slow-growing and rarely metastasize. Nevertheless, they are locally invasive and can be destructive. While typical cases are diagnosed based on clinical findings, the clinicopathological manifestations are varied. Consequently, skin biopsy is essential to confirm the diagnosis and evaluate the risk of recurrence. In the treatment of primary lesions, the initial goal is to complete tumor removal, whether by conventional surgical excision, Mohs micrographic surgery, cryosurgery, electrodesiccation and curettage, topical application of imiquimod or fluorouracil, photodynamic therapy, or radiation therapy. Of these treatments, surgical excision and Mohs surgery are the most commonly used because of their association with a low recurrence rate and the ability to confirm residual tumor pathologically. However, other treatment options may be preferred according to patient condition, tumor location, and risk of recurrence. In the treatment of metastatic or locally advanced lesions, smoothened inhibitors, which inhibit Hedgehog signaling pathway activation, were recently approved and impressive tumor shrinkage effects have been described. Although the exact prognosis of metastatic BCC has not been analyzed, it is probably poor due to the rarity of such condition. However, emerging molecular targeting agents hold therapeutic promise.",
keywords = "Basal cell carcinoma, BCC, Cryosurgery, Incidence, Infiltrative type, Morpheaform type, Nodular type, Photodynamic therapy, Pigmented BCC, Risk classification, Superficial type, Surgical excision, Topical imiquimod",
author = "Keiji Tanese",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11864-019-0610-0",
language = "English",
volume = "20",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Diagnosis and management of basal cell carcinoma

AU - Tanese, Keiji

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Basal cell carcinomas (BCCs) are common skin cancers that tend to appear on sun-exposed skin. Pathobiologically, activation of the Hedgehog signaling pathway characterizes the majority of cases. In general, BCCs are slow-growing and rarely metastasize. Nevertheless, they are locally invasive and can be destructive. While typical cases are diagnosed based on clinical findings, the clinicopathological manifestations are varied. Consequently, skin biopsy is essential to confirm the diagnosis and evaluate the risk of recurrence. In the treatment of primary lesions, the initial goal is to complete tumor removal, whether by conventional surgical excision, Mohs micrographic surgery, cryosurgery, electrodesiccation and curettage, topical application of imiquimod or fluorouracil, photodynamic therapy, or radiation therapy. Of these treatments, surgical excision and Mohs surgery are the most commonly used because of their association with a low recurrence rate and the ability to confirm residual tumor pathologically. However, other treatment options may be preferred according to patient condition, tumor location, and risk of recurrence. In the treatment of metastatic or locally advanced lesions, smoothened inhibitors, which inhibit Hedgehog signaling pathway activation, were recently approved and impressive tumor shrinkage effects have been described. Although the exact prognosis of metastatic BCC has not been analyzed, it is probably poor due to the rarity of such condition. However, emerging molecular targeting agents hold therapeutic promise.

AB - Basal cell carcinomas (BCCs) are common skin cancers that tend to appear on sun-exposed skin. Pathobiologically, activation of the Hedgehog signaling pathway characterizes the majority of cases. In general, BCCs are slow-growing and rarely metastasize. Nevertheless, they are locally invasive and can be destructive. While typical cases are diagnosed based on clinical findings, the clinicopathological manifestations are varied. Consequently, skin biopsy is essential to confirm the diagnosis and evaluate the risk of recurrence. In the treatment of primary lesions, the initial goal is to complete tumor removal, whether by conventional surgical excision, Mohs micrographic surgery, cryosurgery, electrodesiccation and curettage, topical application of imiquimod or fluorouracil, photodynamic therapy, or radiation therapy. Of these treatments, surgical excision and Mohs surgery are the most commonly used because of their association with a low recurrence rate and the ability to confirm residual tumor pathologically. However, other treatment options may be preferred according to patient condition, tumor location, and risk of recurrence. In the treatment of metastatic or locally advanced lesions, smoothened inhibitors, which inhibit Hedgehog signaling pathway activation, were recently approved and impressive tumor shrinkage effects have been described. Although the exact prognosis of metastatic BCC has not been analyzed, it is probably poor due to the rarity of such condition. However, emerging molecular targeting agents hold therapeutic promise.

KW - Basal cell carcinoma

KW - BCC

KW - Cryosurgery

KW - Incidence

KW - Infiltrative type

KW - Morpheaform type

KW - Nodular type

KW - Photodynamic therapy

KW - Pigmented BCC

KW - Risk classification

KW - Superficial type

KW - Surgical excision

KW - Topical imiquimod

UR - http://www.scopus.com/inward/record.url?scp=85061228582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061228582&partnerID=8YFLogxK

U2 - 10.1007/s11864-019-0610-0

DO - 10.1007/s11864-019-0610-0

M3 - Article

C2 - 30741348

AN - SCOPUS:85061228582

VL - 20

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 2

M1 - 13

ER -